Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting

Table 2

Mean change in central retinal thickness, macular neovascularization size, and best corrected visual acuity of 10 treatment-naïve neovascular age-related macular degeneration patients at baseline and during follow-up.

Visit	Mean CRT + SD (μm); -value	Mean MNV size + SD (mm2); -value	Mean BCVA + SD (logMAR); -value
Baseline	461.7 ± 82.9	0.85 ± 1.1	0.67 ± 0.4
4 weeks	351.0 ± 39.1	0.75 ± 1.0	0.51 ± 0.4
8 weeks	327.9 ± 48.1	0.70 ± 1.0	0.47 ± 0.4
16 weeks	333.3 ± 58.4	0.74 ± 1.1	0.478 ± 0.4
20 weeks	343.6 ± 74.3	0.75 ± 1.2	0.55 ± 0.4

BCVA = best corrected visual acuity; CRT = central retinal thickness; logMAR = logarithm of minimal angle of resolution; MNV = macular neovascularization; SD = standard deviation two-tailed Student t-test of visit (week) - baseline.